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 3 
1  INTRODUCTION  
 
Implementing general purpose technologies, steam engine and electricity among them, 
has been the most effective way to improve businesses, industries and whole economies 
(Helpman & Trajtenberg 1994). The latest general purpose technology is information 
technology which still has not achieved its full potential. The most disruptive innovation 
within IT is the Internet. However, in 2009, possibly the second most disruptive one began 
its way to the books of history. 
In 2009, a new digital asset and paying system, Bitcoin, was released by an unknown 
person or group that called itself “Satoshi Nakamoto”. Simply put, Bitcoin is a digital 
currency that has no central bank controlling it. The entire system is decentralized, its 
transactions are automatically verified by users and the public ledger is secured through 
extremely strong encryption (Nakamoto, 2008). Bitcoin is the first implementation of the 
new disruptive technology – blockchain (Antonopoulos, 2014). 
Blockchain will most likely transform the economy similarly to general purpose 
technologies in three phases presented by Helpman and Trajtenberg (1994). First, it will 
increase productivity in form of new products, then the new products are utilized in 
various industry and business processes and lastly companies and other entities of the 
economy change the way they work to match the benefits of the new technology. 
Blockchain is now in both the first and the second phases: New products are constantly 
developed and the financial sector is now the first one beginning to implement blockchain 
to its existing business processes (Swan, 2015). Little academic research has yet been 
done and, according to Yli-Huumo et al. (2016), it has mostly focused on only privacy 
and security. Furthermore, they state that new research must be done on scalability and 
blockchain applications beyond Bitcoin in order to achieve the next step, namely the 
expansion to other industries. This is where I step in. 
The goal of this thesis is to explore how blockchain technology can be utilized in 
pharmaceutical supply chains. I chose this area to focus on, because it is very dependent 
on trust, contracts, negotiations, supervising, human interaction and payments through a 
third party. Product counterfeiting, production and distribution problems, thefts and 
fraudulent drugs cause multi-billion-dollar revenue losses in the world and pose a serious 
threat to public health (Papert, Rimpler & Pflaum, 2016). Blockchain technology can 
tremendously improve performance in all these areas and decrease the risk of the 
aforementioned issues. 
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Furthermore, I examine how the proposed measures would impact Bayer AG, a large life 
science company which was founded in 1863 in Germany and had a revenue of 46.3 
billion euros in 2015 (Bayer, 2016). Its core competencies are “in the areas of healthcare 
and agriculture”, and Bayer Pharmaceuticals division is the largest division measured in 
sales by generating a revenue of 13.7 billion euros in 2015. According to Bayer’s annual 
report 2015 (2016), the division “focuses on prescription products, especially for 
cardiology and women’s healthcare, and on specialty therapeutics in the areas of 
oncology1, hematology2 and ophthalmology3”. Bayer is also a major conductor of research 
and the company spent 4.3 billion euros in research in 2015. 
 
2  CONCEPTS  
 
2.1  Blockchain  
 
Blockchain is a decentralized database which stores accounts and transactions between 
them (Swan, 2015). Due to this functionality, blockchain can be described as a public 
ledger. Yli-Huumo et al. (2016) state that every participant, also known as node, has the 
complete and automatically updated list of records of the transactions on the blockchain 
from the very beginning and the list can be queried, making information about transactions 
retrievable. List of terms related to the blockchain can be found in appendix. 
Figure 1 presents the ledger structure and why the ledger is called a blockchain. Every 
new transaction broadcast to the network arrives at a “pool” of transactions that require 
addition to a block, and therefore blocks consist of several transactions. Every block in 
the list of records refers to the previous one and the network automatically notices if some 
party tries to modify the chain afterwards (Antonopoulos, 2014). All blocks are identified 
with a cryptographic hash (Christidis & Devetsikiotis, 2016). Swan (2015) writes that 
cryptographic hashing transforms data to a fixed size of bits through a mathematical 
algorithm. Antonopoulos (2014) continues that it is “virtually impossible” to find two 
different inputs that give the identical output. Cryptographic hashes cannot be inverted, 
so they keep their original data private. 
                                                
1 Treatment of cancer 
2 Blood diseases 
3 Diseases of the eyeball 
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Figure 1. Blocks linked to a chain (Christidis & Devetsikiotis, 2016). 
The key idea behind the decentralized system is to get rid of third parties (Yli-Huumo et 
al. 2016), for example banks, that now verify transactions. In addition to making 
transactions more efficient, this enables the key breakthrough of the blockchain 
technology: disrupting trust. No trust must be put to middlemen or other users. 
Individuals and organizations can create new accounts for the blockchain network. The 
account numbers are random, and therefore the individuals and organizations behind the 
addresses are not exposed. Transactions are executed with certain units. The units 
represent assets that the users agree upon. Swan (2015) states that they can be physical 
assets (such as real estate, cars and mobile phones), intangible assets (such as bonds, votes, 
patents and licenses) or digital assets (such as images, music and e-books) For example, 
on the Bitcoin blockchain the Bitcoin itself is the unit and represents value in the digital 
currency. Various kinds of assets can exist on one blockchain (Swan, 2015). 
Nakamoto (2008) explains that transactions are executed by creating a transaction 
message that is then broadcast to the whole network so that every node updates their list 
of records appropriately. Nakamoto (2008) also presents the process of accepting new 
transactions as follows: 
1) New transactions are broadcast to all nodes. 
2) Each node collects new transactions into a block. 
3) Each node works on finding a difficult proof-of-work for its block. 
4) When a node finds a proof-of-work, it broadcasts the block to all nodes. 
5) Nodes accept the block only if all transactions in it are valid and not already spent. 
6) Nodes express their acceptance of the block by working on creating the next block in 
the chain, using the hash of the accepted block as the previous hash. 
Next I clarify these steps. In order to prevent fraud, the transactions require a signature to 
prove the sender’s identity. Every account has an individual private key which is a set of 
numbers and letters that is mathematically linked to the account number, also known as 
the public key, as it is visible to other users (Yli-Huumo et al. 2016). One can also think 
of the private key as a password and the public key as an email address to demonstrate 
how they work. 
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Figure 2 demonstrates how a transaction is first signed by a user and then verified by other 
users. A signature is created by putting the message and the private key into a 
cryptographic hash algorithm (Decker & Wattenhofer, 2013). This basically means that 
the signature keeps the transaction message and the private key secret. Antonopoulos 
(2014) explains that in order to check if a signature is valid and belongs to the right account 
number (public key) and transaction message, other users can use another algorithm. 
Because signatures are made of both the message and the private key, they are unique for 
every single transaction. In other words, one can verify that parties and transactions are 
real, but still no information about them is exposed. Hence, no trust is needed between 
parties. For example, on blockchain network one could verify that a user is of age without 
ever knowing their name or date of birth. 
 
Figure 2. Signing and verifying a transaction. 
The signatures indicate the parties of a transaction but not the time of it. The network must 
in some way agree on the order of transactions. According to Swan (2015), before 
blockchain technology, the challenge of all digital payment systems has been the double-
spending problem: digital assets can be copied over and over again and it couldn’t be 
verified if an asset was already spent before. Solving this problem is the key technical 
innovation of blockchain technology. 
Blockchain technology tackles the double-spending problem by requiring computational 
processing work to verify transactions (Decker & Wattenhofer, 2013). This process is also 
called mining. Antonopoulos (2014) explains that “mining is the process of hashing the 
block header repeatedly, changing one parameter, until the resulting hash matches a 
specific target.” The specific target changes every time a new block is created. One can 
Private(key Public(key
Transaction(message
Digital(signature
1oE2ihFvG358tt9gjb9
248gChn420jt8DJx7zB…Signing(
algorithm
Verification
algorithm
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produce a hash result, that matches the specific target, only by randomly guessing the 
input until the desired hash result is found.  
On average, getting the right guess requires trillions of guesses, but when a great number 
of miners are simultaneously working on the task, it gets solved within a few minutes. 
Depending on how many miners participate in the task it can naturally get faster or slower 
to solve the task. In this case, the blockchain is calibrated to change the difficulty of the 
task so that it will always be solved in about ten minutes. 
When the result to the target is found, the solver broadcasts the answer, or proof-of-work, 
to all the nodes of the network and others can prove it automatically (Decker & 
Wattenhofer, 2013), because they can just insert the result to the function and prove that 
it matches to the original target. The solver gets a reward for the computing work provided 
and their block is added to the chain of previous blocks that together make up the list of 
records. Hence the name blockchain technology. Then the process starts again with new 
unverified transactions. 
Because the mining is virtually a guessing game, all miners can get a reward at some point 
and the odds only depend on how much computing power one can provide (Swan, 2015). 
The chance of reward is the motivation to keep mining in the future, too. For example, on 
the Bitcoin blockchain the reward is a certain number of Bitcoins for the solver and this 
is the way new units are created into the system (Antonopoulos, 2014). He continues that 
another way of rewarding miners is to implement a small transaction fee that is then given 
to the successful miner by the user who sent the transaction message in the first place. 
Information in the network doesn’t universally get updated simultaneously, because it is 
transferred node by node. This may occasionally cause several different versions 
(different blocks and thus different transactions) of the blockchain to exist in the network 
if the same mathematical task is simultaneously solved by several miners. Decker and 
Wattenhofer (2013) describe these different versions of a blockchain forks. Every 
blockchain calculates how much computing work it has cumulatively required to produce 
and nodes will eventually adopt the “longest” chain. In a case of three miners solving the 
block simultaneously the longest chain is defined by which chain the next block is first 
added to, as visible in Figure 3. 
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Figure 3. Different versions of one blockchain. The longest one will be adopted in the network. 
This is then the longest chain in the whole network and all nodes will eventually adopt 
this fork (Decker & Wattenhofer, 2013). Taking into account that it takes ten minutes on 
average to create one block, this transition does not take long. This mechanism ensures 
that consensus can be reached in a peer-to-peer network. Because a blockchain can have 
several forks, transactions only become secure after a few further blocks are created. 
Transactions in abandoned forks are transferred back to the pool of unverified transactions 
and get eventually added to the longest chain. 
Because of forks, a blockchain is in theory prone to fraud through intentional double-
spending. Decker and Wattenhofer (2013) describe a situation, where a user could first 
spend units to buy something and after the transaction send another transaction message 
to the network, in which the user transfers the same units back to themselves. If the user 
can beat the odds by solving a new mathematical task for a block that contains their new 
transaction, there is a fraudulent fork in the network (see Figure 4). 
 
 
Figure 4. A fraudulent fork on a blockchain (presented as red). 
The longest chain is the “honest” chain and it gets new blocks added to it continuously by 
all other miners. The fraudulent user would need to solve several mathematical tasks in a 
row to overcome the original chain and get others to use their fork of the blockchain. The 
probability of succeeding is extremely theoretical. According to Swan (2015), in order to 
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get a fraudulent chain to become the longest one in practice one must own more than half 
of the computing power of the whole network (known as 51-percent attack). However, in 
decentralized and global networks it is virtually impossible to achieve. 
To conclude, a blockchain is a decentralized database that works as a public ledger which 
stores accounts and a continuously growing list of transactions. Blockchain technology 
disrupts trust. Every participant in the chain has an automatically updating copy of the 
ledger and consensus of its transactions is automatically reached. This makes central 
intermediaries unnecessary and users do not have to put trust on a third party, such as a 
bank. No trust is needed between strangers on a blockchain, because strong cryptography 
protects users and transactions and maintains total privacy. Blockchain has solved the 
double-spending problem by requiring a huge amount of computational processing work 
to validate transactions. The transactions are then added to the blockchain and cannot be 
modified afterwards. This makes the chain reliable and safe to use. 
 
2.2  Smart  contracts  
 
The fundamental function of blockchain technology is handling asset transfers, as 
explained in the previous section. However, transactions are not the only function 
blockchains enable. The idea of smart contracts was first introduced by Szabo (1994). He 
described them as “a computerized transaction protocol that executes terms of a contract”. 
In other words, smart contract is a paragraph of code that represents a contract and is 
digitally signed by parties. It is autonomous in the sense that the contract and its issuer do 
not need to be in further contact after deployment (Swan, 2015). Unlike a conventional 
legal agreement smart contracts are automatically executed and enforced if agreed terms 
occur after signing, thus replacing trust with functioning software and erasing the need for 
a third party enforcer. Christidis and Devetsikiotis (2016) clarify that smart contracts are 
deterministic and, unlike legal contracts, are not prone to ambiguity: the same input 
always produces the same output. Bitcoin blockchain does not support smart contracts 
(Swan 2015) and currently users of Bitcoin utilize smart contracts by using parallel 
blockchains outside Blockchain network that improve its protocol. The most developed 
blockchain platform that also enables usage of smart contracts in the same environment is 
Ethereum.4 Unlike Bitcoin that only provides a pre-defined set of operations, Ethereum is 
                                                
4 Ethereum (2016). Homestead documentation. Retrieved from: 
http://www.ethdocs.org/en/latest/ 
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a re-programmable blockchain so that new applications can be developed on its platform. 
This contributes to Ethereum’s goal to be “adaptable and flexible”, thus becoming a 
universal platform for developing and using blockchain-based applications. 
In the example of Figure 3, a smart contract to sell the admin rights of a website is created 
on Ethereum’s blockchain. The code is represented in a protocol language EtherScript 
which makes the underlying code readable to laymen (see Figure 5). 
 
Figure 5. Example of a smart contract. Source: “What is Ethereum?” EtherScripter, 2016, 
http://etherscripter.com/what_is_ethereum.html. Accessed on November 8th 2016. 
 
Smart contracts are naturally applicable in digital environment only and cannot 
automatically enforce agreements in the physical world. Internet-of-Things applications 
must be implemented in order to achieve that (Christidis & Devetsikiotis, 2016).  
 
Only after introduction of blockchain technology have smart contracts become relevant in 
practice. The secure digital currency of blockchain technology provides a “convenient 
billing layer” (Christidis & Devetsikiotis, 2016) and automates all contractual conditions 
because for the first time contracts and objects of contracts reside in the same digital 
environment. Smart contracts are their own units that exist on the blockchain and they can 
be spectated by every node of the network. 
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2.3  Pharmaceutical  supply  chain  
 
Pharmaceutical supply chains are very different from typical supply chains that start with 
extracting raw materials and after a few production phases continue with shipping to stores 
and selling to end customers. The products in the chain are different, too. Shah (2004) 
describes the life cycle of drugs: Before the typical processes of manufacturing and 
distribution start it usually takes 10 years to come up with a new potential drug, after 
which it is protected by a patent. Then another 6-8 years are required for safety and 
efficacy tests and manufacturing processes. 
Failures in pharmaceutical supply chains may even cause death for the end user. 
According to Chircu et al. (2014) pharmaceutical supply chains have undergone 
transformations during the last decades. These include strict and diversified regulations 
and requirements of compliance, complex distribution channels, faster expiration of 
patents, new requirements of drug safety and the eternal fight against product 
counterfeiting. 
As the basis of my research I will use the model of a generic global pharmaceutical supply 
chain (Figure 6) created by Chircu et al. (2014). 
 
Figure 6. Generic global pharmaceutical industry supply chain (Chircu et al. 2014). 
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The supply chain in Figure 4 is divided into three parts: discovery and development, 
production, and delivery and dispensing. In addition, there are two kinds of intermediaries 
involved: service and information intermediaries. Service intermediaries mainly provide 
logistics services and information intermediaries exchange data with companies of the 
supply chain. 
 
3  PARTICIPATING  ENTITIES  AND  INFORMATION  FLOW  
 
Although blockchain technology was originally intended to be truly public and distributed 
(i.e. public blockchain), private blockchains have also been developed (Swan 2015). 
Private blockchains limit access to them and they are controlled by one or more entities. 
Otherwise, public and private blockchains do not differ from one another. According to 
Christidis & Devetsikiotis (2016) private blockchains are more suitable “for stakeholders 
who operate in a controlled, regulated environment or who wish a higher throughput than 
a public network could offer”. They argue that mining on a public blockchain requires 
more computational power than in private ones and it tends to cost more, because miners 
must be rewarded in one way or another. Also, transactions are computationally more 
efficient, because fewer nodes participate in the mining process. 
The financial industry is now developing blockchain technology to make their existing 
business processes more efficient and there is a consensus that private blockchains are the 
correct solution for them (Swan, 2015). Even the Nordic bank Nordea has joined a 
partnership of 25 major banks to develop blockchain solutions for the financial services.5 
Taking into account that pharmaceutical supply chains also act in a controlled and 
regulated environment, I suggest a private blockchain to be implemented. 
I believe that the private blockchain platform should be developed and implemented by a 
governmental organization that is responsible for supervision of medicines already. 
Consequently, I see that the private blockchain in the EU should be hosted by the 
European Medicines Agency, or short “EMA”, that “is responsible for the scientific 
evaluation, supervision and safety of medicines developed by pharmaceutical companies 
for use in the EU” (EMA, 2016). A medicine agency’s task on the pharmaceutical 
blockchain is to authorize stakeholders willing to join the network, monitor their actions 
                                                
5 Larsson, P. (2015, October 28). Nordea joins groundbreaking technology partnership. Nordea. 
Retrieved from http://www.nordea.com/en/press-and-news/ 
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and medicines and provide information so that only trusted stakeholders are let to do 
business on the blockchain. 
As mentioned earlier, the generic pharmaceutical supply chain represented in Figure 4 is 
the basis of the pharmaceutical supply chain, but not all stakeholders of the chain need to 
have access to the shared ledger. The main objective of the shared ledger is to provide 
safe medicine and make information, material and cash flows more efficient and secure. I 
present, which stakeholders should join the network. 
Starting from the beginning of the (forward) supply chain, the first stakeholders required 
are R&D labs. Based on their work, I suggest that new patents are created which will exist 
on the blockchain as intangible assets, and drug producers can buy rights for production 
with the help of smart contracts. The suppliers of R&D labs are not required to join the 
blockchain, because their products will not end up in the medicines transported through 
the supply chain. 
Drug production facilities are represented on the blockchain. Their suppliers providing 
raw materials for drug production are in the network, too. I present that by certifying raw 
material producers and monitoring material flow from them to production facilities, the 
risk of counterfeit drugs can be lowered. Suppliers of production equipment are not 
required on the blockchain, because they only take part in production, not the supply chain 
itself. 
All the stakeholders in delivery and dispensing are represented in the network, as they are 
involved in the supply chain and medicines are distributed through them. These include 
delivery facilities, wholesalers, hospitals, clinics, pharmacies, government buyers and the 
end users – patients. Patients are included in the network if they purchase medicines 
themselves (through pharmacies) and thus determine themselves, which medicine should 
be used in which situation. For example, in hospitals staff is responsible for giving the 
right drugs and hospitals make the last purchase of the supply chain before consumption 
of the product. 
All service intermediaries contribute to at least one of the three flows of the supply chain 
(cash, information, materials) and thus they should be included on the blockchain. For 
example, third-party transporters can provide information regarding location of the 
product and drug disposal service providers can automatically be rewarded for disposing 
of drugs. 
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Information intermediaries play a big role on the blockchain. As stated earlier, a 
government-run regulatory agency should host the blockchain, but also other 
organizations can be included in the network in order to gather vital information regarding 
the pharmaceutical supply chain. These organizations can include NGOs and 
organizations that unite companies in the industry. 
As explained in Section 2.1, blockchain technology enables verifying transactions and 
participating entities without revealing the information and the entities themselves to the 
public. This is achieved by encryption and the combination of private and public keys. 
Considering the pharmaceutical supply chain, this allows regulators, supervisors and other 
stakeholders to verify secure transactions and still lets business partners maintain their 
trade secrets. For the first time competitors may share all their transactions with one 
another and still protect their privacy. 
As Bayer Pharmaceuticals is active in both R&D and production phases in the supply 
chain, it benefits greatly from the new blockchain platform. Now that only relevant and 
trusted stakeholders participate in the network, it is easier for Bayer to find new business 
partners among both subcontractors and service providers, and choose partners through 
competition and bidding. For example, choosing raw material suppliers and insurance 
providers can now safely be done based on competition on price, as the quality is ensured. 
According to Bayer’s annual report 2015 (2016), most of Bayer’s products are covered by 
patents. Commercializing new products is vital for the company to continue R&D work 
in the future, too. Still, it takes a lot of time from the patent application to market launch 
and Bayer only has a few years before the patents expire (Bayer, 2016). Thus, 
improvements in protecting and commercializing patents can have an enormous impact 
on the bottom line. On the blockchain, patents are secured with strong encryption so that 
virtually no intellectual property may be stolen. Furthermore, smart contracts allow 
flexible ways to commercialize patents, as stated earlier. In Bayer’s case, the company 
could, for example, sell rights to limited usage of its patents before they expire in order to 
lower motivation to contest patents before expiration.  
 
4  CONTRACTS  AND  PAYMENTS  
 
As explained in Section 2.2, smart contracts provide an efficient way of creating and 
executing contracts on a blockchain, because contracts themselves and assets involved in 
them exist in the same digital environment. 
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An example: Person A wants to sell an apartment that she owns and creates a smart 
contract that states the terms of the agreement: If blockchain units worth of 100,000 euros 
are sent to their account, the sender will automatically gain ownership over the apartment. 
Person A broadcasts this smart contract to other users of the network and soon person B 
fulfils the agreement by sending the required amount of money. All stakeholders of the 
blockchain can now verify that person B owns the apartment in question. 
Still, this does not necessarily mean that person A will hand over the physical key and 
move out from the apartment. Agreements made on the blockchain must in some way be 
enforced in the physical world. Christidis and Devetsikiotis (2016) propose that Internet-
of-Things (IoT) applications can provide a solution to this challenge. They even present 
an example of smart electronic locks that can only be unlocked by using the owner’s 
digital signature. This way person A would be enforced to leave the apartment that person 
B now owns in our example. The smart electronic lock is a simple example of smart 
property: property whose ownership is controlled on a blockchain (Swan, 2015). 
Chircu et al. (2014) explore possibilities of radio-frequency identification (RFID) tags in 
pharmaceutical supply chains and find that the technology can tremendously improve for 
example product security and cost efficiency. These findings are very similar to benefits 
of blockchain technology and the combination of these two is very suitable for 
pharmaceutical supply chains. In pharmaceutical supply chains, products are shipped in 
bulk (Chircu et al. 2014), and Asif and Mandviwalla (2005) also state that pallet-level 
tagging is much more cost efficient than item-level tagging. Consequently, RFID tags can 
be installed to packages to track product location (Christidis & Devetsikiotis, 2016). As 
seen in Figure 5, RFID tags can keep track of the whereabouts of products in the supply 
chain and automatically inform the location on the blockchain. If a signed smart contract 
has a term to deliver the package to a certain destination, this information can be verified 
with the help of RFID tags that broadcast the message on the blockchain and thus to the 
smart contract (Figure 7). 
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Figure 7. Product tracking and payment with RFID tags on blockchain (Christidis & Devetsikiotis 2016). 
The contract is now fulfilled and both the payment and the change in ownership are 
executed automatically and simultaneously. Smart electronic locks could also be installed 
to packages, and only the party who has ownership over the products inside could open 
the package. Other benefits of the combination of RFID and blockchain technology are 
discussed in Section 5. 
Blockchain environment enables executing smart contracts in real time, but it also 
provides a payment network for machine-to-machine transactions (Swan, 2015). IoT 
powered machines linked to blockchain can be programmed to perform various tasks 
independently. In pharmaceutical supply chains, I see that independent machines would 
be valuable for monitoring stock levels and making smart contracts to order more supplies 
when required. 
With the help of smart contracts and devices linked to the Internet-of-Things, many 
business processes can be automated and thus supply chains can become leaner than ever 
before. Swan (2015) even represents the concepts of decentralized autonomous 
application (Dapp) and decentralized autonomous organization (DAO). She describes 
these as “increasingly complex and automated smart contracts that become more like self-
contained entities, conducting pre-programmed and eventually self-programmed 
operations”. In other words, smart contracts can be programmed to a level, where they act 
like independent applications or even organizations on the blockchain. 
Before this becomes reality, I propose that the combination of IoT devices and smart 
contracts should be used to automate processes in determining, negotiating and executing 
contracts. Comparable to software that buys and sells stocks, smart contracts could be 
programmed to negotiate contracts according to pre-determined algorithms. For instance, 
an RFID sensors of a production facility could keep track of raw materials coming in and 
going out of the facility and, when the stock level reaches a pre-determined low-point, 
contact suppliers and negotiate the best contract from the facility’s point of view. 
Essential challenge in issuing smart contracts is to determine when the conditions of a 
contract are met. Some conditions can be measured by IoT devices themselves (for 
instance number of products in stock and weather conditions) but often external 
information is needed to determine conditions that are met. Swan (2015) calls these 
external sources of information oracles and raises the question of which sources can be 
trusted by the entire network. She uses the example of a smart contract that is issued to 
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share heritage after a person passes away. An external source is needed so that smart 
contract can determine when this condition is met. 
A company called Oraclize6 is tackling this issue by developing a generic oracle service 
that acts “as a data carrier”. It connects to web APIs and delivers required information to 
blockchains and thus to smart contracts. Oraclize provides cryptographic proof to show 
that information was not altered by the oracle. The source of the information must still be 
trusted, though. For the pharmaceutical supply chain Oraclize provides inspiration. 
As the pharmaceutical blockchain would be run by a governmental agency, I suggest that 
a government-run oracle service is integrated onto the blockchain. As stakeholders 
anyway consent to state-run environment, it is only logical to provide the oracle service 
as state-run. Like Oraclize, the service would connect to web APIs and share information 
with the blockchain. In addition, I propose that stakeholders may request the oracle to get 
access to various sources. This means that smart contract issuer still decides what source 
is reliable, and the oracle just transfers that data safely utilizing cryptographic proof. Of 
course, the oracle could proactively offer reliable sources, for example material from the 
state-run Statistics Finland. 
The Bitcoin blockchain’s goal is to implement its own decentralized digital currency that 
gets rid of fiat currency. A fiat currency is a currency, the usage of which is determined 
by law in a country (Selgin & White, 1999). Virtually every current currency worldwide 
is a fiat currency. As the pharmaceutical blockchain does not strive to run its own 
independent currency, I see that a connection to the fiat currency must be formed. It is 
possible to exchange Bitcoins to fiat money on external platforms (Antonopoulos, 2014). 
As Bitcoin also fluctuates, the exchange rate varies over time. 
Companies on the pharmaceutical blockchain will eventually want to exchange their 
assets to fiat money and thus fluctuating value of assets poses a major risk for trade. In 
order to avoid fluctuation, I suggest that the government controls the exchange of assets 
to fiat money. In practice, companies would “buy in” to the network by paying a certain 
amount in fiat money to the host. The buyer then gets an equivalent number of assets on 
the blockchain and they can always exchange their assets back to fiat money from the 
host. 
This process is comparable to how casinos issue playing chips to players. As a result of 
this process, the host virtually creates a new regulated currency that has a fixed exchange 
                                                
6 http://docs.oraclize.it/ 
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rate to other currencies. This process also is the way how new value is created in the 
network, so unlike on the Bitcoin blockchain, mining does not generate new value on the 
chain. 
As banks and other central intermediaries are not involved in transactions, international 
trade within the supply chain becomes faster and more cost efficient. Now it takes a couple 
of days for banks to transfer money between each other internationally. On the blockchain, 
all stakeholders act in one single environment and transactions take place in real time. In 
order to verify a transaction one must only wait for a few more blocks to be added on top 
of the block which contains the transaction in question. Direct international transfers pose 
challenges in taxation, too, due to varying taxation policies between countries. 
Walport (2016) suggests, though, that blockchain technology can also be used for 
collecting value-added tax (VAT). According to him, if EU-wide standards and protocols 
are developed, collecting VAT in the EU can be performed on a blockchain. This would 
“reduce the administrative burden imposed on other organizations” and “increase 
transparency of real-time transactions” (Walport, 2016). Collecting VAT would be 
proactive instead of retroactive, as it is nowadays. I see it unrealistic that all transactions, 
where VAT applies, can be controlled on one general blockchain in the near future. Thus, 
I suggest that after EU-wide standards exist the implementation would be started one 
industry at a time. As the blockchain for pharmaceutical supply chain would be controlled 
by an EU-wide organization (EMA) automatic collection of VAT could be implemented 
when developing the blockchain environment. 
As public ledgers blockchains could automatically provide all accounting services a 
company needs from bookkeeping to reporting taxes and closing the books (Swan, 2015). 
This would also be proactive instead of retroactive like collecting VAT. As I stated earlier, 
I find it unrealistic to see one general blockchain in the near future. Still, companies can 
benefit from automatic accounting. The real-time accounting gives real-time information 
regarding budgets, income and costs and companies can respond to unwanted changes 
more quickly. 
Bayer Pharmaceuticals can directly utilize all the proposed measures presented in this 
section. International trade becomes more efficient and secure via direct payments and 
RFID tags combined with smart locks on the blockchain. Machine-to-machine 
transactions combined with smart contracts are beneficial for Bayer in maintaining 
appropriate stock levels in production. The company’s workload in accounting and 
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taxation reduces significantly with the help of blockchain platform, as Pharmaceuticals is 
the largest division of the company measured in sales. 
Oracle services would benefit Bayer especially in developing more flexible smart contract 
terms. Referring to the flexible patent rights mentioned in the previous section, the 
company could, for instance, allow patent usage only when the demand peaks higher than 
what Bayer can independently manufacture. This situation in the markets can be 
determined, for example, by comparing medicine sales and production, or even 
proactively by forecasting epidemics globally and reacting to them before they reach the 
market in question. 
 
5  LOGISTICS,  TRANSPARENCY  AND  PRODUCT  SECURITY  
 
Continuing with RFID implementation in pharmaceutical supply chains described by 
Chircu et al. (2014), RFID tags “can improve communication of data and information, 
reduce counterfeiting, and enable monitoring of drug quality in supply chain”. According 
to them, RFID tags are suitable for keeping up pharmaceutical supply chain regulations 
because the tags are easily readable without line of sight, are tamper-proof, have 
mechanical and chemical stability, and additional sensors can be added for data collection. 
Chircu et al. (2014) developed a tentative model for RFID usage in pharmaceutical supply 
chains. Their model “uses RFID passive tags as well as temperature and motion sensors, 
coupled with a central infrastructure that enables tracking and tracing of items”. Chircu et 
al. (2014) observed a pilot model launch and stakeholders involved in it were satisfied by 
the results. In my view, the problem of their model is the “Pharmaceutical Trust Center”, 
which sets up the infrastructure of servers and databases and verifies all products. All 
stakeholders are required to trust this central intermediary which may act dishonestly or 
fail to deliver its responsibilities. Also, RFID tags cannot in general identify if the reader 
device can be trusted, which may lead to unauthorized access to the tags (Asif & 
Mandviwalla, 2005). 
In my view, combining RFID and blockchain technology the aforementioned challenges 
can be solved while still retaining all the benefits of RFID tags. On a blockchain a central 
intermediary is unnecessary and on the suggested pharmaceutical chain the only 
verification process takes place when new stakeholders join the network. This regulated 
access to the network provides one layer of security, as the participating parties have been 
at least once verified by the governmental body hosting the network. RFID tags linked to 
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an asset on the blockchain are also secure, thanks to strong encryption the blockchain 
provides. Only devices of the current owner of the goods can read the encrypted 
information, as they have the private key that makes the information readable. 
In the pharmaceutical supply chain RFID tags could provide package metadata, when they 
are read with a permitted device. This could include place of origin, time of production, a 
map of its travel to the current destination with GPS information and client contact 
information, among others. Chircu et al. (2014) interviewed manufacturers, wholesalers 
and end users who had participated in the pilot model and they confirmed that RFID tags 
lower the cost of human error and make deliveries more efficient. Especially in the end of 
the supply chain, when the package has reached for example doctors and patients, having 
easily accessible and reliable information can prevent errors in treatment (Chircu et al. 
2014). 
RFID tags enable tracking of products, but implementing the proposed blockchain 
technology makes tracking and tracing automatically available for every stakeholder in 
the network. The attached sensors proposed by Chircu et al. (2014) make drugs more 
secure, as they give a signal for example if transportation conditions are poor or if the 
package is opened during transportation. Blockchain improves sharing information 
regarding damaged or fraudulent assets (products), because every node on the blockchain 
can immediately notice if a certain asset is not secure. 
The combination of RFID tags and IoT devices linked to blockchain provides 
improvements in product security. The smart electronic locks introduced in Section 4 
prevent unauthorized access to goods and blockchain controls access to the lock. If the 
package is accessed by an unauthorized person with force, the RFID tag notifies the whole 
network of a damaged package and can inform the location of the package in case of theft. 
Bayer AG is now implementing an innovation of their own for battling counterfeit drugs. 
The company has developed software called BayCoder7 which works like a QR code, but 
randomizes the serial numbers on pharmaceutical packages so that only one in ten 
thousand possible serial numbers is real. This means that only one counterfeit product in 
then thousand will not be identified when comparing the serial number to the central 
database provided by Bayer. I still find problems in this solution. Although the serial 
number cannot virtually be faked anymore, BayCoder does not provide the benefits of 
RFID tags: tracking and being tamper-proof. The central database provided by Bayer also 
contradicts with blockchain principles. With the suggested blockchain and IoT 
                                                
7 Bayer (2016). Hard Times for Counterfeiters. Bayer technology solutions Magazine, 1, 46-49. 
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combination, Bayer can also raise the level of privacy in the supply chain, as explained in 
the next paragraph. 
Cryptographic functions and combination of public and private keys enable transactions 
on blockchain to be verified without exposing the content of them, as explained in Section 
2.1. In the pharmaceutical supply chain this provides transparency, privacy and security 
simultaneously. Trusted parties make transactions with one another, verify that the 
products were produced in trusted sources and transported by trusted stakeholders and still 
keep the content of a transaction private. 
I see that in the suggested pharmaceutical supply chain stakeholders can, in practice, trade 
goods in two ways. The first way is using smart contracts as explained in the previous 
section. Smart contracts are available for every stakeholder if they can just deliver the 
terms of the contract. The second way is a more conventional one: direct trade with 
another party. I propose that the host of the network would keep the list of participants 
public and therefore stakeholders could communicate with each other. In case of a 
negotiated outcome, parties can just share their public keys so that transactions can be 
performed. Knowing other parties’ public keys still does not expose their privacy and 
trade secrets. As described in Section 2.1, transaction messages are encrypted and digital 
signatures require both the private key and the message to be created. So by only knowing 
other party’s public key one cannot make any conclusions on the blockchain. 
 
6  BLOCKCHAIN  INFRASTRUCTURE  AND  GOVERNANCE 
 
Setting up the blockchain platform for the pharmaceutical supply chain is a task of a 
governmental body. In the EU, this would fall to European Medicines Agency, as 
discussed in Section 3. The platform will be a private blockchain, because it is controlled 
by a governmental body and access to the network is controlled. New value is generated 
on the blockchain via the host that exchanges fiat money to assets on the chain, as 
explained in Section 4. Thus, mining does not generate new value to the network. 
The platform must enable smart contract usage similarly to Ethereum platform in order to 
facilitate trade, which was discussed in Section 4. The “rules” of the blockchain must be 
programmed during development – for example, authorization of new participants and 
collection of taxes. A functioning user interface, enabling all the functionalities discussed 
in this thesis, must also be developed. Furthermore, I believe that the user interface must 
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provide means for communication so that direct transactions between parties are easier to 
carry out. Blockchain networks are connected via Internet (Antonopoulos 2014) and the 
pharmaceutical supply chain network should be accessed with its own software that runs 
for example on computers, tablets and mobile devices. 
According to Christidis and Devetsikiotis (2016), mining on a private blockchain is more 
efficient than on public ones, because fewer nodes participate in verifying transactions. 
Furthermore, they state that not all nodes need to mine and not all miners need to be 
involved in transactions. If only certain stakeholders would mine, consensus could be 
reached faster and therefore lighter algorithms for reaching consensus can be used 
(Christidis & Devetsikiotis, 2016). This would lead to shorter slack in adding new blocks 
to the chain and thus shorter transaction verification time. Another scenario with external 
miners would mean that the ledger is public, although not everyone is allowed to 
participate in transactions and smart contracts. This scenario would require an incentive 
(reward) for the external miners to provide their computational power. Furthermore, 
Christidis and Devetsikiotis (2016) state that if only the trusted transacting nodes of a 
network perform the mining, there is virtually no risk of the 51-percent attack, where one 
party can tamper the ledger. 
Taking these arguments into account, I suggest that on the pharmaceutical supply chain 
platform no external miners should provide computational process work for verifying 
transactions. The consequences of a 51-percent attack would be too harmful considering 
that healthcare depends on continuous supply of medicines. When mining is limited to the 
participating nodes, either the host (governmental agency) or all approved nodes can 
perform the computational work. When mining is distributed between several locations, 
the risk of malfunctioning software and hardware is far lower. Thus, I propose that it is 
mandatory to provide computational processing work when entering the network. 
Bayer AG should, consequently, provide computational power for mining in the network. 
As mining is very similar to maintaining a data center, the company needs to establish a 
new facility that can run thousands of computers inside. The Nordics are a suitable 
location for data centers, thanks to developed infrastructure, cool weather and access to 
green energy, and the market is growing strongly8. Bayer already runs a significant 
                                                
8 Smolaks, M. (2015, September 10). Nordic data center market expected to triple power by 
2017. DatacenterDynamics. 
Retrieved from: http://www.datacenterdynamics.com/content-tracks/design-build/nordic-data-
center-market-expected-to-triple-power-by-2017/94767.fullarticle 
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pharmaceutical production site in Turku, Finland (Bayer, 2016) and, in my opinion, could 
establish the new “mining center” in the same area. 
An exception for the mandatory mining can, in my view, be allowed for individuals. For 
instance, patients that simply utilize the blockchain to verify the authenticity of their 
medicine with the help of a cell phone cannot provide much hardware to maintain the 
platform. The option is to have “lightweight clients” (Antonopoulos, 2014), which do not 
store the entire list of records on their hardware and thus do not participate in mining. 
They can just create an account that is then approved by the host, for example by verifying 
their identity and citizenship via bank account, and then connect to the network by 
downloading software. Lightweight clients can perform transactions and queries with the 
help of user interface and other nodes approve their actions. 
 
7  CONCLUSION  
 
In this thesis, I have studied what benefits blockchain technology can have on 
pharmaceutical supply chains and how it should be utilized in practice. I started the thesis 
with presenting the essential concepts of blockchain, smart contract and pharmaceutical 
supply chain. Then the benefits and implementation were discussed in the parts of 
participating entities and information flow, contracts and payments, logistics, 
transparency and product security, and also blockchain infrastructure and governance. 
Blockchain technology provides a platform for transactions and contracts. The distributed 
database verifies transactions automatically, but still privacy and trade secrets are safe. 
No central intermediary is needed to perform transactions on the blockchain. One cannot 
tamper the ledger and transactions are secured via strong encryption. Blockchain 
technology disrupts trust, because users do not have to put trust on a third party 
intermediary and other users are automatically verified by the network. Smart contracts 
provide a way of automatically negotiating and executing contracts and the payments 
connected to them on the blockchain. 
Pharmaceutical supply chain should implement a private blockchain that is developed and 
controlled by a governmental organization that supervises medicines already. This host 
then verifies stakeholders willing to join the network. These stakeholders include, for 
example, production facilities, transporters, wholesalers and end users. Stakeholders are 
responsible for processing transactions (mining), but individual end users can join as 
lightweight users that do not provide computational power for the network. Transactions 
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on the blockchain are based on exchanging assets that represent real property or value in 
the physical world. The host of the network exchanges fiat money to assets on the 
blockchain and this way the network can trade with existing currencies. The host also 
provides an oracle service that connects the blockchain to external information, which 
widens the scale of possibilities of smart contract applications. 
Products moving in the pharmaceutical supply chain are attached with an RFID tag and 
in some cases additional Internet-of-Things (IoT) devices in order to keep track of their 
whereabouts and to collect data. These devices also contribute to product security, as they 
can provide smart locks and inform if a package was opened violently without permission. 
The combination of smart contracts and IoT devices automates trade and even enables 
machine-to-machine transactions. The platform can also automate taxations and 
accounting within the blockchain. 
As a bachelor’s thesis the scope of this thesis was narrowed to only exploring benefits and 
potential implementation of blockchain network for the pharmaceutical supply chain. 
Further research could and should be done in testing the suggestions of this thesis in 
practice. In my view, this work could be started by studying potential stakeholder’s 
capability of joining the blockchain network in the first place. In more detail, this would 
mean studying, for example, stakeholder’s capability to provide computational power, 
providing smart contract based insurance, the host’s ability to maintain a trusted oracle 
and a study case of end user’s expectations of software functionalities. Another research 
field is to compare the benefits and implementation between different industries or, more 
specifically, between different supply chains. 
In general, studying potential applications of blockchain technology still requires an 
enormous amount of work and I am eager to follow the results of future research. 
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9  APPENDIX  
  
List  of  terms  and  explanations  in  blockchain  technology  
51-percent attack Having more than half of the entire network’s 
computational power to create fraudulent 
transactions to double-spend money (see 
double-spending below). The only way to 
double-spend on a blockchain. 
 26 
Cryptographic hashing Transforming data to a fixed size of bits 
through a mathematical algorithm. Makes the 
message in question unreadable. 
Double-spending problem Successfully spending exact same money 
more than once. Blockchain tackles this 
problem by requiring mining to verify 
transactions (see below). 
Fork Alternative chain that has partly different 
blocks included. A part of the network 
considers the fork correct. Eventually forks 
will disappear automatically. 
Mining Process of adding transaction blocks to the 
chain. Performed by solving a cryptographic 
function by guessing the correct answer. 
Mining requires an enormous amount of 
computational processing work. 
Oracle A server outside the blockchain that transmits 
information for smart contracts. 
Private blockchain Blockchain network with limited and 
regulated access to it. 
Private key Every account has a code (private key) that 
the owner uses to verify their own 
transactions. Comparable to password. 
Proof-of-work The result of successful mining. The solution 
to the aforementioned cryptographic function. 
Public blockchain Blockchain network that everyone can 
participate in. 
Public key Number that presents account address in the 
network. Comparable to email address or 
bank account number. 
 
